SCHEMBL146734

SCHEMBL146734

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)NCC1CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.67
PDGFRB P09619 10/20 0.67
FGFR1 P11362 9/20 0.67
PRKAA1 Q13131 7/20 0.67
MET P08581 6/20 0.67
PRKAA2 P54646 6/20 0.67
EGFR P00533 4/20 0.67
PTK2B Q14289 4/20 0.67
KIT P10721 3/20 0.67
NEK2 P51955 3/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
PLK4 O00444 3/20 0.67
DCLK1 O15075 3/20 0.67
ROCK2 O75116 3/20 0.67
RPS6KA5 O75582 3/20 0.67
MAP4K4 O95819 3/20 0.67
NTRK1 P04629 3/20 0.67
INSR P06213 3/20 0.67
LCK P06239 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144785 0.94 KDR (0.69) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL144209 0.90 KDR (0.62) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL144651 0.90 KDR (0.67) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL144378 0.89 KDR (0.66) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL148704 0.89 KDR (0.62) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL146016 0.89 FGFR1 (0.64) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL148478 0.88 KDR (0.61) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL144118 0.87 KDR (0.61) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL144615 0.87 PDGFRB (0.61) KDRPDGFRBFGFR1PRKAA1MET
SCHEMBL141110 0.87 KDR (0.67) KDRPDGFRBFGFR1PRKAA1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885PDGFRB 348/4885FGFR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.